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Post‑transplant absolute 
lymphocyte count predicts 
early cytomegalovirus infection 
after heart transplantation
Minjae Yoon1,2, Jaewon Oh1,2, Kyeong‑Hyeon Chun1, Chan Joo Lee1 & Seok‑Min Kang1*
Immunosuppressive therapy can decrease rejection episodes and increase the risk of severe and fatal 
infections in heart transplantation (HT) recipients. Immunosuppressive therapy can also decrease the 
absolute lymphocyte count (ALC), but the relationship between early post‑transplant ALC and early 
cytomegalovirus (CMV) infection is largely unknown, especially in HT. We retrospectively analyzed 
58 HT recipients who tested positive for CMV IgG antibody and received basiliximab induction 
therapy. We collected preoperative and 2‑month postoperative data on ALC and CMV load. The 
CMV load > 1200 IU/mL was used as the cutoff value to define early CMV infection. Post‑transplant 
lymphopenia was defined as an ALC of < 500 cells/μL at postoperative day (POD) #7. On POD #7, 29 
(50.0%) patients had post‑transplant lymphopenia and 29 (50.0%) patients did not. The incidence of 
CMV infection within 1 or 2 months of HT was higher in the post‑transplant lymphopenia group than 
in the non‑lymphopenia group (82.8% vs. 48.3%, P = 0.013; 89.7% vs. 65.5%, P = 0.028, respectively). 
ALC < 500 cells/μL on POD #7 was an independent risk factor for early CMV infection within 1 month 
of HT (odds ratio, 4.14; 95% confidence interval, 1.16–14.77; P = 0.029). A low ALC after HT was 
associated with a high risk of early CMV infection. Post‑transplant ALC monitoring is simple and 
inexpensive and can help identify patients at high risk of early CMV infection.
Opportunistic infections represent a significant problem after transplantation. Cytomegalovirus (CMV) infec-
tion remains the most common infections after solid organ transplantation, resulting in significant morbidity 
and related  mortality1–3. Current antiviral agents and preventive strategies after solid organ transplantation have 
led to a decrease in the incidence of CMV diseases, and current guidelines recommend CMV prophylaxis or 
preemptive therapy after  transplantation4, 5.
In heart transplantation (HT), the appropriate use of immunosuppressive agents is crucial to prevent graft 
 rejection6. Induction therapy, an intense prophylactic treatment strategy, is thought to be related to lower acute 
rejection in the early post-transplant period. Basiliximab, a monoclonal antibody for interleukin-2 (IL-2), and 
anti-thymocyte globulin (ATG), a polyclonal anti-lymphocyte antibody, are the most commonly used induction 
drugs for  HT7, 8. These immunosuppressive agents can decrease rejection  episodes9, but they can increase the 
risk of severe and fatal infections in HT  recipients8, 10–12. In South Korea, there is a high prevalence (> 90%) of 
CMV seropositivity among the general population, similar to other  countries13, 14. Therefore, immunosuppressive 
therapy including induction therapy can be related to a higher risk of CMV infection after  HT15, 16.
Immunosuppressive therapy after transplantation can decrease the absolute lymphocyte count (ALC) and 
their  functions17. A low CD4 + cell count represents a major risk factor for the development of opportunistic 
infections in HIV  patients18. Hence, it is a standard of care to use the CD4 + cell count clinically to guide the ini-
tiation of prophylactic HIV antimicrobial agents. The lymphocyte count is a simple and inexpensive measurable 
value. The general concept that low lymphocyte count indicates inadequate reserves to mount an appropriate 
immunologic response can be extended to opportunistic infections after transplantation. Several studies have 
considered the relevance of lymphocyte count for identifying and monitoring patients at risk for post-transplant-
related  infections19–23. Recent studies have suggested that pre-transplant low ALC could be a risk factor for CMV 
infections after  transplantation24, 25. However, the relationship between early post-transplant ALC and early CMV 
infections is largely unknown, especially in HT.
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We hypothesized that a low ALC after HT correlates with a higher risk of early CMV infection. Therefore, 
we investigated the peri-transplant ALC and its association with the incidence of early CMV infection in HT 
recipients.
Methods
Study design. We performed a retrospective analysis of patients who underwent HT from January 2013 to 
August 2016 at a tertiary university-affiliated hospital (Severance cardiovascular hospital, Seoul, South Korea). 
During this period, all recipients were CMV immunoglobulin G (IgG) antibody positive (R +), and they all 
received basiliximab induction therapy, followed by triple maintenance immunosuppressive therapy (tacroli-
mus, mycophenolate mofetil, and corticosteroids). Patients received basiliximab induction (20 mg intravenous 
[IV] infusion) on postoperative day (POD) #0 and #4. Immediately after the operation, 500 mg of methylpred-
nisolone was administered, followed by 125 mg every 8 or 12 h for 3 days with the administration of tacrolimus 
and mycophenolate mofetil. Then, 1  mg/kg/day of prednisolone was administered and tapered to 5  mg/day 
weekly. From a total of 70 patients, we excluded the patients who died before POD #14, had no CMV load data, 
or were aged < 16 years (Supplementary Figure S1 Online). Finally, we enrolled 58 patients who underwent HT. 
All patients were followed up till 60 days after HT.
In our institute, for CMV prevention, we used preemptive therapy in CMV seropositive HT recipients (R +) 
according to the current  guidelines5, 26. Preemptive therapy was defined as the administration of anti-CMV 
agents only to asymptomatic patients with evidence of early CMV replication to prevent CMV  disease27. For 
CMV preemptive therapy, we used intravenous ganciclovir (10 mg/kg/day) or oral valganciclovir (1800 mg/
day), with the doses adjusted for renal impairment until the resolution of CMV DNAemia, with a minimum of 
2 weeks of treatment.
Baseline demographic data and comorbidities were evaluated. In addition, CMV load, anti-CMV agent use, 
peri-transplant ALC, and acute graft rejection within 2 months after HT were collected for analysis. Endomyo-
cardial biopsy was performed to confirm the diagnosis of acute graft rejection according to the International 
Society for Heart and Lung Transplantation (ISHLT) grading system, similarly as our previous study—Grade 
0, no rejection; Grade 1R, mild; Grade 2R, moderate; or Grade 3R,  severe28, 29. This study was approved by the 
Institutional Review Board of Yonsei University Hospital (4–2013-0665) and was conducted in accordance with 
the Declaration of Helsinki. Informed consent from the patients was obtained.
Definition of CMV infection and the measurement of CMV load. In accordance with the 
 guidelines5, 30, we defined CMV infection as evidence of CMV replication regardless of symptoms, defined as 
virus isolation or detection of viral proteins or nucleic acid in any body fluid or tissue specimen. CMV disease 
was defined as evidence of CMV infection with attributable symptoms.
We performed quantitative nucleic acid testing by extracting CMV DNA from whole blood. Real-time poly-
merase chain reaction (PCR) for CMV DNA was performed using a Light Cycler 480 (Roche Diagnostics, 
Germany) and Bio-Core CMV Quantification real-time PCR kit (Bio-Core, Korea)31. For the standardization of 
results, the World Health Organization International Standard for human CMV for nucleic acid amplification 
techniques was used. The CMV load data was reported in IU/mL and measured at least weekly until 2 months 
after HT.
Recently, the guidelines reported the need for establishing a universal viral load threshold for initiating 
preemptive  therapy5, 32. However, the standardization of specific cutoff values is limited because of variations in 
the performance of tests and the diversity of the patient population. By considering previous studies about the 
viral load  threshold33–36, our institute has used a CMV load > 1200 IU/mL as a threshold for initiating preemptive 
therapy. Although any detectable CMV load (e.g., 1000 IU/mL) is included in the definition of CMV infection 
according to the guidelines, we use the “early CMV infection” term in this study when the highest value of the 
CMV load within 1 or 2 months after HT is more than 1200 IU/mL.
Measurement of ALC. We measured ALC by collecting blood samples. ALC was calculated using the fol-
lowing formula: ALC = White blood cell (WBC) count × lymphocyte percent. We collected preoperative and 
2-month postoperative ALC data. Post-transplant lymphopenia was defined as an ALC of < 500 cells/μL based 
on previous  studies24. In sensitivity analysis, we performed similar analysis by changing the cutoff value of ALC 
from 500 to 610 cells/μL based on another recent  study37. We stratified patients by the presence of post-trans-
plant lymphopenia on POD #7.
Statistical analysis. Descriptive statistics were used to characterize baseline characteristics and comor-
bidities. Categorical variables are reported as frequencies (percentages). Continuous variables are expressed as 
medians with interquartile range. The categorical variables were compared using Fisher’s exact test or the Pear-
son chi-square test, and continuous variables were compared using the Mann–Whitney U-test. Risk factors for 
early CMV infection were identified using univariable and multivariable binary logistic regression analyses. All 
tests were two-tailed, and differences were considered significant at P < 0.05. Statistical analyses were performed 
using SPSS version 25.0 statistical package (SPSS Inc., Chicago, IL, USA).
Results
Baseline characteristics of heart transplantation. The baseline characteristics of patients are listed 
in Table 1. There were 29 (50%) patients with post-transplant lymphopenia on POD #7, and 29 (50%) patients 
without post-transplant lymphopenia on POD #7. There were no significant differences in terms of the various 
parameters of donors. The recipient age of the post-transplant lymphopenia group was significantly greater than 
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that of the non-lymphopenia group (52 [44–57] years vs 46 [33–53] years, P = 0.048). There was no significant 
difference between the groups in other baseline co-morbidities of recipients. Pre-transplant ALC and ALC on 
POD #7 were significantly lower in the post-transplant lymphopenia group than in the non-lymphopenia group 
(1110 [630–1330] cells/μL vs. 1480 [1030–1910] cells/μL, P = 0.003, for pre-transplant ALC and 330 [250–380] 
vs. 840 [690–1100] cells/μL, P < 0.001, for ALC on POD #7, respectively). There was no significant difference in 
the underlying heart diseases of recipients between the groups.
Time course of ALC following HT. The time courses of median value of ALC following HT are shown 
in Fig. 1. Patients were stratified by the occurrence of early CMV infection within 1 month of HT. The pre-
transplant ALC levels were not significantly different between the groups. In addition, there were no significant 
differences in ALC on PODs #0, 1, 3, and 5. However, ALC on PODs #7, 14, 21, and 30 were significant lower 
in the early CMV infection group than in the no early CMV infection group. The distribution of ALC on POD 
#7 in patients who had early CMV infection within 1 month after HT (n = 38) and those who did not (n = 20) is 
shown in Fig. 2. The median ALC in the early CMV infection group was significantly lower than that in the no 
early CMV infection group (380 [290–680] cells/μL vs. 840 [340–1240] cells/μL, P = 0.005).
Post‑transplant CMV infection outcomes. Table 2 summarizes the post-transplant outcomes stratified 
by ALC on POD 7. The post-transplant lymphopenia group (ALC on POD #7 < 500 cells/μL) had a higher inci-
dence of CMV infection within 1 or 2 months of HT than the non-lymphopenia group (1 month: 83% vs. 49%, 
P = 0.013; 2 months: 90% vs. 66%, P = 0.028, respectively). ALC on PODs #14, 21, and 30 were significantly lower 
in the post-transplant lymphopenia group than in the non-lymphopenia group (all P < 0.05). In addition, the 
prevalence of allograft rejection within 2 months of HT was not significantly different between groups.
Table 1.  Baseline characteristics of the study population stratified by the ALC on POD #7. Values are 
expressed in numbers (%), or median (interquartile range). ALC = absolute lymphocyte count, BMI = body 








(n = 29) P value
Donors
Age (years) 41 (30–46) 41 (34–46) 38 (28–45) 0.141
Female sex, n (%) 24 (41) 10 (35) 14 (48) 0.286
Height (m) 1.67 (1.61–1.75) 1.67 (1.63–1.75) 1.68 (1.60–1.75) 0.601
Weight (kg) 66.0 (58.1–75.8) 69.0 (58.1–76.4) 65.0 (58.7–70.3) 0.750
BMI (kg/m2) 23.5 (21.5–25.3) 23.6 (21.6–25.6) 23.4 (21.6–25.1) 0.926
BSA  (m2) 1.77 (1.63–1.91) 1.80 (1.59–1.94) 1.73 (1.63–1.84) 0.686
LVEF (%, median [IQR]) 60 (56–65) 58 (55–65) 61 (58–70) 0.068
Recipients
Age (years) 50 (38–57) 52 (44–57) 46 (33–53) 0.048
Female sex, n (%) 38 (66) 21 (72) 17 (59) 0.269
Height (m) 1.66 (1.59–1.71) 1.67 (1.58–1.70) 1.64 (1.60–1.71) 0.963
Weight (kg) 60.0 (53.7–69.6) 60.5 (55.5–70.0) 60.0 (52.0–69.1) 0.479
BMI (kg/m2) 22.8 (20.1–24.9) 23.3 (20.2–25.2) 21.2 (20.5–24.0) 0.371
BSA  (m2) 1.67 (1.54–1.82) 1.68 (1.59–1.84) 1.65 (1.53–1.82) 0.549
Pre-transplant LVEF (%, median [IQR]) 19 (16–27) 19 (16–25) 21 (16–27) 0.870
Previous heart surgery, n (%) 15 (26) 9 (31) 6 (21) 0.368
Hypertension, n (%) 19 (33) 11 (38) 8 (28) 0.401
Diabetes mellitus, n (%) 13 (22) 6 (21) 7 (24) 0.753
CMV-seropositive, n (%) 58 (100) 29 (100) 29 (100) –
Pre-transplant total WBC count (cells/μL, median [IQR]) 7160 (3750–10,510) 6380 (3510–10,460) 7390 (5310–10,380) 0.451
Pre-transplant ALC (cells/μL, median [IQR]) 1250 (800–1710) 1110 (630–1330) 1480 (1030–1910) 0.003
ALC on postoperative day 7, (cells/μL, median [IQR]) 470 (320–840) 330 (250–380) 840 (690–1100)  < 0.001
Underlying heart disease, n (%)
    Ischemic cardiomyopathy 13 (22) 6 (21) 7 (24) 0.999
    Dilated cardiomyopathy 19 (33) 9 (31) 10 (35) 0.999
    Valvular heart disease 6 (10) 4 (14) 2 (7) 0.666
    Congenital heart disease 5 (9) 2 (7) 3 (10) 0.999
    Others 15 (26) 8 (28) 7 (24) 0.881
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Figure 1.  Time course of median value of ALC following heart transplantation. ALC = absolute lymphocyte 
count, CMV = cytomegalovirus, POD = postoperative day.
Figure 2.  Distribution of ALC on postoperative day 7 in patients who had early CMV infection 
within one month after HT (n = 38), and those who did not (n = 20). ALC = absolute lymphocyte count, 
CMV = cytomegalovirus, HT = heart transplantation.
Table 2.  Post-transplant outcomes stratified by the ALC on POD #7. Values are expressed in numbers (%) 
or the median (interquartile range). ALC = absolute lymphocyte count, CMV = cytomegalovirus, HT = heart 




(n = 29) P value
Early CMV infection within 1 month of HT, n (%) 24 (83) 14 (49) 0.013
Early CMV infection within 2 months of HT, n (%) 26 (90) 19 (66) 0.028
CMV disease within 2 months of HT, n (%) 4 (14) 1 (3) 0.349
Anti-CMV therapy initiated within 2 months of HT, n (%) 26 (90) 21 (72) 0.180
Valganciclovir, n (%) 1 (3) 2 (7) 0.999
Ganciclovir, n (%) 25 (86) 19 (66) 0.028
Time from transplant to CMV onset (days, median [IQR]) 18 (11–24) 22 (15–36) 0.019
Acute graft rejection within 2 months of HT by endomyocardial biopsy, n (%)
    Grade 0 12 (52) 10 (40) 0.080
    Grade 1R, 10 (44) 15 (60) 0.123
    Grade 2R 1 (4) 0 (0) 0.490
    Grade 3R 0 (0) 0 (0) –
ALC on POD #14, (cells/μL, median [IQR]) 380 (240–540) 690 (430–920) 0.001
ALC on POD #21, (cells/μL, median [IQR]) 340 (240–550) 730 (510–1040)  < 0.001
ALC on POD #30, (cells/μL, median [IQR]) 390 (240–540) 850 (640–1260)  < 0.001
5
Vol.:(0123456789)
Scientific Reports |         (2021) 11:1426  | https://doi.org/10.1038/s41598-020-80790-4
www.nature.com/scientificreports/
Post‑transplant low ALC as a risk factor for early CMV infection. The logistic regression of risk fac-
tors for early CMV infection within 1 month of HT is shown in Table 3. Univariable regression analysis revealed 
a significant association between early CMV infection within 1 month of HT and the following variables: age, 
decrease in ALC on POD #7, an ALC of < 500 cells/μL on POD #7, and an ALC of < 610 cells/μL on POD #7. 
Multivariable regression analysis was performed by using total three variables: age, sex, and ALC < 500 (or 600) 
cells/μL on POD #7. Multivariable analysis revealed that an ALC of < 500 cells/μL on POD #7 was an independ-
ent risk factor for the early CMV infection within 1 month of HT after adjusting age and sex (Model 1: odds 
ratio [OR], 4.14; 95% confidence interval [CI], 1.16–14.77; P = 0.029). In sensitivity analysis, an ALC cutoff value 
of < 610 cells/μL was used, and among the 3 parameters retained in a multivariable regression analysis model 2, 
age and ALC < 610 cells/μL on POD #7 prevailed as independent predictors for the early CMV infection within 
1 month of HT. Similar logistic regression analysis was performed on the risk factors for early CMV infection 
within 2 months of HT (Supplementary Table S1 online). In Univariable regression, an ALC of < 500 cells/μL on 
POD #7 was associated with higher early CMV infection within 2 months of HT (OR, 4.56; 95% CI, 1.10–18.86; 
P = 0.036). Total leukocyte count on pre-transplant or POD #7 were not the predictor of early CMV infection 
within 1 month in our study (Supplementary Table S2 online).
Discussion
In this study, we performed analysis with the purpose of obtaining information regarding the ALC after HT 
and its relationship with the incidence of early CMV infection. Our principal findings are as follows: (1) ALC 
on PODs #7, 14, 21, and 30 was significantly lower in the early CMV infection group than that in the no early 
CMV infection group; (2) post-transplant lymphopenia group on POD #7 had a higher incidence of early CMV 
infection than the non-lymphopenia group; and (3) an ALC of < 500 cells/μL on POD #7 was an independent risk 
factor for early CMV infection in HT. These results can be translated clinically to indicate that close monitoring 
of ALC after HT may help identify patients at high risk of early CMV infection.
A recently published study showed that a low ALC at the end of CMV treatment completion was an independ-
ent predictor for recurrent CMV diseases in solid organ transplant  recipients23, compatible with our findings. 
Another study from the Mayo clinic also reported that nonspecific and CMV-specific CD8 + T cell functions 
correlated with the course of CMV after solid organ  transplant38. These findings may be biologically plausible 
considering the importance of T cell immunity in maintaining CMV latency in transplant recipients. Post-
transplant ALC monitoring is simple and inexpensive; hence, it could help identify patients at high risk of early 
CMV infection, considering the high cost of CMV load monitoring.
In general, ALC is affected not only by induction therapy but also by anti-CMV agents, other medications used 
for HT (e.g., mycophenolate mofetil, steroid), or CMV infection itself. Considering most preemptive therapies 
for CMV are initiated at least 2 weeks after HT in our study, we focused on the ALC on POD #7. Thus, the effect 
of anti-CMV agents or CMV infection on ALC on POD #7 could be minimalized. Further, ALC on POD #7 is 
ideal for reflecting the effect of induction therapy because patients received basiliximab induction therapy on 
PODs #0 and #4. The consequence of our study is that low ALC after heart HT can be used in predicting early 
CMV infection. Therefore, more frequent monitoring of the CMV load or early aggressive initiation of anti-CMV 
treatments for preemptive therapy could be considered in post-transplant lymphopenia group.
Some studies on induction therapy after transplantation may suggest that we need more individualized induc-
tion strategies for decreasing the risk of both infection and rejection. For instances, considering the long half-life 
of basiliximab (14–21 days), single (vs. double dose) or decreased (two 10 mg vs. 20 mg) doses of basiliximab 
induction therapy could be individualized options for selected HT  recipients39, 40. In addition, some institutions 
have used the ALC-guided ATG dosing strategy (e.g., targeted to < 100–200 cells/mm3) after ATG induction in 
solid organ transplantation (especially the kidney). It has also been mentioned in the current ISHLT guidelines 
for the care of HT recipients as class IIb indications and the level of evidence  C6. Therefore, serial monitoring 
of ALC during the peri-operative period may be another individualized option for immunologic monitoring in 
HT recipients to decrease the risk of infection and rejection.
Table 3.  Univariable and multivariable logistic regression analysis of risk factors for early CMV infection 
within 1 month of heart transplantation. ALC = absolute lymphocyte count, CI = confidence interval, 






OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age 1.06 1.01–1.10 0.011 1.05 1.01–1.11 0.037 1.06 1.00–1.11 0.042
Female 0.80 0.27–2.38 0.685 1.62 0.42–6.22 0.484 1.48 0.39–5.59 0.563
Decrease in pre-transplant ALC (per 100 
cells/μL increment) 1.08 0.99–1.18 0.095
Decrease in ALC on POD #7 (per 100 
cells/μL increment) 1.22 1.05–1.41 0.009
ALC < 500 on POD #7 versus ALC ≥ 500 
cells/μL 5.14 1.53–17.20 0.008 4.14 1.16–14.77 0.029
ALC < 610 on POD #7 versus ALC ≥ 610 
cells/μL 5.20 1.62–16.78 0.006 4.01 1.12–14.08 0.025
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CMV infection after transplantation is associated with numerous indirect effects, such as an increased risk 
of acute rejection, chronic allograft failure, and other opportunistic  infections41–43. Recently, some studies have 
reported a significant association between CMV infection and cardiac allograft vasculopathy (CAV); however, in 
one study, a significant effect of CMV infection on the risk of CAV was seen only among HT recipients who had 
CMV breakthrough infection while receiving  prophylaxis44–46. Because of its negative impact, CMV prevention 
is a major focus of post-transplant management, which can be accomplished either by preemptive or antiviral 
prophylaxis. Hence, serial monitoring of ALC can decrease severe CMV disease and result in a low incidence 
of allograft rejection and CAV after transplantation. Further studies are warranted to prove this hypothesis.
Limitations. This study has some limitations. First, this study was a single-center, retrospective study with 
statistical power limited by the number of cases and outcomes. Second, we did not have any data for HT patients 
with ATG induction therapy. Third, the donor CMV serostatus could not be investigated. However, consider-
ing that the current guidelines recommend CMV prophylaxis or preemptive therapy for seropositive recipients 
regardless of donor serostatus, it was reasonable to use preemptive therapy in all CMV seropositive recipients 
in our study. Fourth, our institution used a comparably low CMV load (= 1200 IU/mL) as threshold for pre-
emptive therapy initiation. Consequently > 80% of the patients received ganciclovir or valganciclovir therapy, 
often within the first 2 post-transplant weeks, with these medications by themselves suppressing the bone mar-
row and could have caused or contributed to the lymphopenia. Therefore, larger studies are required to confirm 
our observation and recently favored less cautious strategies for initiation for antiviral  therapy5, 33 have to be 
considered by clinical programs. Fifth, some patients started preemptive therapy within one or two weeks post-
transplant, so the low ALC on POD #7 could have been related to very early CMV infection or antiviral therapy. 
Despite these limitations, our findings were internally consistent and supported those of other similar studies.
Conclusion
In conclusion, low ALC after HT was associated with a higher risk of early CMV infection. Close monitoring of 
ALC after HT may help to identify patients at a high risk of early CMV infection.
Data availability
Study data are available from the corresponding author on reasonable request.
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